The Potential Domino Effect of Tennessee’s HIV Federal Funding Cuts

Jennifer Lockwood headshot

Publisher’s Note: Since we first published this piece by Jennifer Lockwood of Ravin Consultants, there has been an important development that is addressed at the end of the story. We thank Jennifer and her team for alerting us and recommending that we republish the article with their update.

SPONSORED CONTENT

On January 17th 2023, a letter was sent from the Tennessee Department of Health (DOH) to Tennesseans serving “as notification of changes in the HIV Program.”  The letter informed federal grantees that they will no longer receive CDC funded HIV ‘in-kind support and services’ and will need to find their own financial means by June 1, 2023.

This means cash-strapped safety net providers treating HIV and STD patients will no longer receive federal funding for such essential items as condoms, lubrication, HIV and/or Hepatitis testing kits, prevention materials, or any other support services.

Let the dominoes

Read More »

AIDS Advocates Holding Weeklong Protest Over Gilead’s 340B Contract Pharmacy Restrictions and Changes In Patient Assistance Program

AIDS advocates with placards protesting Gilead policy
AIDS advocates are holding a week long series of protests outside Gilead's California headquarters.

AIDS Healthcare Foundation (AHF) members are staging a weeklong, twice-daily series of protests at drug maker Gilead Science’s Northern California headquarters to protest the company’s policy to impose conditions on 340B providers that use contract pharmacies to dispense 340B-priced drugs.  

Read More »

Lifting of Title X Gag Rule Could Spur Hundreds of Clinics to Rejoin 340B

A September 2019 protest in Cleveland against the Trump administration rule barring Title X-funded family clinics from providing abortion referrals.

Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era rule barring them from providing abortion referrals might return to Title X and 340B soon.

The U.S. Department of Health

Read More »

340B Providers Might Insure HIV-at-Risk Patients in Response to Gilead’s PrEP Reimbursement Cuts

340B covered entities are bracing for a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.

340B covered entities are exploring buying health insurance for patients at risk of contracting HIV in response to a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.

Gilead announced in April that, effective

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report